Eno Research Announces Publication Showing Activated Clinoptilolite (Zeolite) Safely Removes Toxic Heavy Metals through Urinary Excretion

Share Article

Eno Research has published the results of its recent study in the November issue of the Journal of Nutrition and Dietary Supplements that supports the use of an activated clinoptilolite (Zeolite) to increase urinary excretion of toxic heavy metals.

Past News Releases


Eno Research & Consulting Services, a pharmaceutical and biotechnology contract research organization, has announced today that it has published the positive results of its recent clinoptilolite (Zeolite) study in the Journal of Nutrition and Dietary Supplements.

The article, entitled "Clinical evidence supporting the use of an activated clinoptilolite suspension as an agent to increase urinary excretion of toxic heavy metals", presents data collected in a placebo-controlled human clinical study that demonstrates dietary supplementation with an activated clinoptilolite suspension safely increases removal of heavy metals from the body through urinary excretion. In particular, the study showed significant increases in the urinary excretion of aluminum, antimony, arsenic, bismuth, cadmium, lead, mercury, nickel and tin.

"We are excited about publishing the results of our recent study, as it represents a major breakthrough in our understanding of the detoxification process through the use of activated clinoptilolite," explained James Flowers, President and Chief Scientific Officer of Eno Research. "Additionally, by using a commercially available form of activated clinoptilolite, marketed as Natural Cellular Defense (NCD), we were able to show clinical evidence using a product that is already available to consumers," he concluded.

To download the full-text article, visit DovePress, publisher of the Journal of Nutrition and Dietary Supplements: http://www.dovepress.com/articles.php?article_id=3696

About Eno Research & Consulting Services
Founded in 2003, Eno Research & Consulting Services, LLC (ERCS) is headquartered in Hillsborough, NC. With a highly trained and dedicated staff, ERCS is equipped to offer all levels of research and development services. The company possesses the range of expertise necessary to service the international pharmaceutical industry as well as the small biotech company.


Share article on social media or email:

View article via:

Pdf Print